Department of Medicine
Peter Riedell is a hematology/oncology physician with a particular interest in the treatment of lymphoma using cellular and immunotherapy approaches. He is especially focused on the evaluation of novel, targeted therapies and immunotherapies. As a 2016 Lymphoma Research Foundation Scholar for the Lymphoma Clinical Research Mentoring Program, he investigated the efficacy of integrating a new BTK (Bruton’s tyrosine kinase) inhibitor (ACP-196) with standard mantle cell lymphoma (MCL) treatment, which frequently includes chemotherapy followed by an autologous stem cell transplant, to determine whether this combination leads to improved patient outcomes.
Riedell received a BS in biology from Southern Methodist University and an MD from the University of Tennessee College of Medicine. He completed his internal medicine residency at Washington University School of Medicine/Barnes-Jewish Hospital in St. Louis and a clinical fellowship in hematology and oncology at Washington University School of Medicine in St. Louis. He was honored with the Gerald L. Plitman MD Internal Medicine Award, the Kipnis-Daughaday Teaching Award, and a Knowlton Incentive for Excellence Award. He also obtained a graduate certificate in clinical investigation from Washington University School of Medicine in St. Louis.